aiPTO - Brain Cancer Treatment Innovation

Revolutionize Brain Cancer Therapy

About

Brain tumors, both primary and metastatic, are devastating diseases where effective treatments remain elusive. Over a thousand clinical trials have failed, largely due to the lack of translatable preclinical models. AIPTO, an official spinoff from the German Cancer Research Center (DKFZ), tackles this grand challenge with the disruptive technology platform integrating next-generation patient avatars and generative agentic AI. Our mission is to revolutionize brain cancer therapy and deliver personalized effective treatments.

IPTO: Brain organoid (green) with tumor cells (red). Source: Liu/DKFZ

Next-generation Patient Avatar

The Individualized Patient Tumor Organoid (IPTO) technology cultures intact patient tumor explants supported by brain organoids. These next-generation patient avatars are diagnostically indistinguishable from parental tumors, closely mirror tumor microenvironments at the molecular level, faithfully capture diverse cell types and proportions, and are able to predict clinical outcomes for brain cancer patients.

Generative agentic AI

Leveraging unique single-cell data generated by patient avatars, a multi-agent generative AI system deciphers drug response at the single-cell level, reveals mechanisms of action, predicts resistance, and recommends personalized treatment plans with counter-resistance strategies.

Revolutionizing Drug Discovery and Precision Medicine

Integrating patient avatars and AI, AIPTO's platform enhances success rates across the entire drug discovery and precision medicine pipeline—from target discovery and lead validation to patient stratification, companion diagnostics, and personalized treatment planning. We empower strategic partners at every stage of their pipelines while advancing our own proprietary programs.